vaccin
consid
one
success
medic
action
greatli
contribut
improv
world
health
inde
strikingli
reduc
preval
mani
infecti
diseas
thu
help
nowaday
save
million
live
year
vaccin
administr
aim
induc
har
protect
effector
memori
immun
compris
neutral
antibodi
ab
togeth
cytotox
helper
cell
abl
control
subsequ
challeng
target
pathogen
liveattenu
kill
wholepathogen
origin
administ
vaccin
purpos
due
safeti
concern
includ
import
reactogen
risk
revers
use
subunit
vaccin
prefer
latter
compos
recombin
purifi
pathogenderiv
antigen
entiti
mostli
deplet
innat
immun
stimulu
requir
coadministr
adjuv
andor
use
deliveri
vehicl
achiev
suffici
immunogen
last
decad
import
piec
work
field
vaccin
technolog
allow
ration
design
develop
formul
ensur
effici
induct
immun
respons
synthet
micronanoparticl
liposom
immun
stimul
complex
iscom
virosom
viruslik
particl
well
emuls
offer
sever
interest
attribut
vaccin
deliveri
alreadi
proven
effici
parenter
intramuscular
subcutan
vaccin
induc
protect
infecti
agent
formul
design
mimic
biophys
biochem
featur
pathogen
thu
ensur
effici
display
deliveri
concentr
amount
antigen
ag
adjuv
innat
adapt
immun
cell
interestingli
lead
reduc
number
inject
requir
elicit
potent
cellular
humor
immun
respons
minim
cytotox
despit
import
success
protect
individu
mani
deleteri
patholog
situat
remain
licens
subunit
vaccin
administ
parenter
howev
except
previous
infect
individu
rout
administr
induc
limit
protect
effect
level
mucos
surfac
site
vast
major
pathogen
agent
gain
access
host
bodi
addit
mechan
epithelium
cover
mucu
chemic
antimicrobi
peptid
barrier
found
mucosa
adapt
humor
cellular
immun
prime
import
effici
protect
pathogen
insult
thu
reinforc
effici
vaccin
deliveri
vaccin
formul
directli
mucosa
repres
asset
well
accept
immun
respons
elicit
local
ensur
effici
imprint
effector
memori
b
cell
home
mucos
tissu
limit
entri
colon
spread
pathogen
licens
mucos
vaccin
consist
administr
liveattenu
kill
wholepathogen
rais
similar
safeti
concern
parenter
inject
subunit
vaccin
approv
human
use
mainli
due
technic
difficulti
inher
administr
rout
physiolog
tissu
vaccin
formul
appli
identifi
adequ
vaccin
formul
deliver
mucos
remain
challeng
due
fact
contrast
parenter
vaccin
inject
ag
adjuv
directli
contact
antigenpres
cell
apc
ag
sampl
perform
across
mucu
epithelium
first
deleteri
acid
proteolyt
dynam
environ
mucos
surfac
impact
stabil
integr
retent
time
appli
ag
tolerogen
natur
mucosa
impair
induct
effector
immun
antigen
entiti
lack
suffici
immunostimulatori
signal
hurdl
may
howev
partial
overcom
thank
recent
progress
made
understand
mucos
immun
field
vaccin
technolog
apart
immunolog
physiolog
aspect
one
import
point
consid
vaccin
complianc
patient
pediatr
vaccin
administr
minim
invas
easi
perform
abil
vaccin
larg
number
peopl
countri
endem
infect
present
access
medic
infrastructur
limit
great
import
well
context
parenter
vaccin
appropri
strategi
inject
invas
pain
requir
trainedskil
medic
staff
administr
moreov
pose
problem
relat
risk
associ
infect
site
inject
needlestick
injuri
spread
transmiss
diseas
dispos
use
materi
thu
increas
demand
needlefre
vaccin
exampl
mucos
vaccin
display
sever
advantag
eas
administr
selfdeliveri
allow
mass
vaccin
absenc
needleassoci
risk
case
lower
cost
simplifi
product
due
absenc
administr
devic
mucos
applic
subunit
vaccin
formul
develop
success
test
mainli
limit
number
safe
effici
deliveri
system
adjuv
avail
coupl
sometim
import
amount
ag
administ
review
focu
lipidbas
micronanoparticl
possess
sever
desir
characterist
interest
agdeliveri
system
vaccin
biocompat
overcom
physiolog
barrier
mucosa
promot
ag
cross
epithelium
uptak
apc
protect
associ
payload
adequ
incorpor
adjuv
may
display
mucoadhes
properti
order
achiev
induct
protect
antipathogen
humor
cellular
respons
relev
mucos
surfac
choic
potent
administr
rout
care
consid
take
account
physiolog
immunolog
featur
differ
target
tissu
aspect
strategi
specif
target
vaccin
portal
entri
across
epithelium
increas
effici
deliveri
first
discuss
howev
direct
vaccin
appropri
locat
suffici
ensur
optim
vaccin
effect
architectur
size
surfac
chemistri
particl
prime
import
manipul
influenc
intens
type
immun
respons
physicochem
properti
lipidbas
particl
ag
incorpor
mucoadhes
associ
adjuv
discuss
next
exampl
mucos
applic
formul
anim
model
outcom
present
final
overview
current
evalu
lipid
particl
open
challeng
mucos
vaccin
human
consid
mucos
surfac
continu
expos
challeng
numer
environment
ag
present
exampl
food
air
deriv
pathogen
commens
microorgan
lumen
top
epitheli
barrier
cover
mucu
secret
antimicrobi
peptid
special
complex
immun
network
call
mucosaassoci
lymphoid
tissu
involv
immunosurveil
mucos
tissu
lymphoid
cell
effector
molecul
secretori
iga
siga
chief
ab
molecul
oper
mucos
surfac
cytokin
chemokin
tightli
orchestr
protect
infect
mainten
toler
toward
endogen
unharm
microorgan
sampl
agent
deliveri
immun
cell
underneath
epitheli
layer
take
place
via
direct
uptak
dc
within
epithelium
across
special
epitheli
cell
name
microfold
cell
respons
select
transport
macromolecul
particul
ag
microorgan
intern
via
cell
occur
differ
mechan
clathrinco
endocytosi
actindepend
phagocytosi
macropinocytosi
depend
natur
ag
cell
present
follicleassoci
epithelium
separ
intestin
lumen
apic
side
underli
immun
cell
basolater
side
peyer
patch
pp
b
intestin
isol
lymphoid
follicl
c
nasopharynxassoci
lymphoid
tissu
nalt
bronchialassoci
lymphoid
tissu
balt
structur
compos
innat
adapt
immun
cell
includ
function
differ
dc
subset
b
cell
dc
integr
signal
deriv
sens
lumin
environ
releas
solubl
factor
cytokin
chemokin
orchestr
gener
tightli
control
mucos
immun
local
migrat
region
lymph
node
ln
addit
paracellular
transcellular
uptak
macromolecul
small
particl
across
epithelia
lead
uptak
apc
outsid
induct
site
induct
local
immun
via
region
ln
contrast
urogenit
tract
oral
caviti
stratifi
epithelium
contain
cell
sampl
occur
dc
interspers
within
tissu
lead
induct
immun
respons
exclus
drain
ln
upon
encount
microorgan
vaccin
formul
mucos
dc
combin
neighbor
epitheli
cell
control
express
specif
home
receptor
prime
lymphoid
cell
modul
type
ensu
immun
respons
imprint
reli
express
sitespecif
integrin
chemokin
receptor
b
cell
allow
transit
via
lymph
blood
migrat
differ
mucos
site
recircul
lymphocyt
gut
requir
express
wherea
migrat
airway
oral
caviti
reproduct
tract
reli
lselectin
case
pathogen
infect
danger
signal
gener
sens
microorgan
switch
immun
respons
toward
effector
type
respons
reli
humor
cellular
arm
elimin
infect
immun
exclus
neutral
siga
well
product
cytokin
activ
phagocyt
induct
cytotox
cell
contribut
protect
mucos
surfac
therefor
major
aim
vaccin
would
elicit
specif
b
cell
respons
relev
site
induc
specif
siga
provid
first
line
protect
invad
pathogen
togeth
appropri
cellular
immun
respons
elimin
pathogen
pathogeninfect
cell
exampl
requir
proper
b
cell
isotypeswitch
gener
iga
respons
includ
mainli
product
retino
acid
pp
cell
togeth
interact
follicular
helper
cell
b
cell
thu
vaccin
formul
mucos
applic
design
best
induc
immunolog
environ
rout
mucos
administr
characterist
balanc
pro
con
vaccin
consid
take
account
pathogen
fight
formul
deliv
howev
standard
studi
avail
directli
compar
safeti
profil
induc
immun
respons
effici
protect
section
consid
differ
mucos
administr
rout
oral
nasalpulmonari
studi
one
sublingu
recogn
promis
way
vaccin
vagin
rectal
deliveri
also
studi
scarc
even
though
power
respons
usual
elicit
local
induct
adjac
tissu
common
mucos
immun
system
predict
home
distant
mucos
tissu
possibl
howev
certain
degre
compartiment
allow
imprint
cell
migrat
everi
mucos
site
flexibl
allow
select
appropri
rout
vaccin
induc
protect
immun
respons
desir
site
note
recent
work
demonstr
transcutan
immun
potenc
promot
induct
immun
respons
abil
traffic
gut
airway
although
low
consist
howev
aspect
cover
review
describ
elsewher
nasal
administr
repres
promis
rout
mucos
vaccin
nasal
tissu
display
rel
larg
surfac
ag
absorpt
cover
thin
layer
mucu
highli
vascular
requir
deliveri
high
ag
dose
eg
compar
oral
administr
noninvas
easili
access
selfadministr
nasal
vaccin
allow
gener
broad
rang
ab
cell
respons
differ
mucos
site
upper
preferenti
lower
airway
mucosa
local
secret
salivari
gland
urogenit
tract
also
elicit
concomit
robust
system
immun
howev
nasal
environ
presenc
proteas
local
ph
togeth
rel
high
mucoscillari
clearanc
rate
may
impact
vaccin
integr
retent
time
thu
affect
gener
immun
respons
major
drawback
concern
safeti
nasal
administr
physiolog
function
smell
percept
might
alter
vaccineinduc
inflamm
close
relationship
brain
might
promot
health
problem
thu
everi
vaccin
candid
evalu
care
safeti
sometim
achiev
nasal
deliveri
directli
target
pulmonari
immun
allow
vaccin
formul
directli
access
respiratori
tract
interest
due
high
permeabl
larg
surfac
area
high
densiti
apc
alveolar
macrophag
dc
b
cell
rout
administr
preferenti
induc
immun
respons
lower
airway
interestingli
shown
promot
cellular
humor
respons
gut
howev
effici
deliveri
lung
easi
task
deliveri
via
nasal
pulmonari
rout
necessarili
lead
similar
outcom
exampl
pulmonari
vaccin
shown
effect
nasal
counterpart
protect
mycobacterium
tuberculosi
infect
differ
immun
mechan
involv
one
administr
rout
inde
elev
level
siga
produc
lung
pulmonari
vaccin
equival
respons
observ
nasal
passag
addit
product
lung
follow
pulmonari
vaccin
import
fight
tuberculosi
wherea
appar
role
cytokin
nasal
environ
oral
administr
repres
interest
strategi
term
eas
deliveri
patient
complianc
safeti
howev
due
intrins
high
dilut
vaccin
formul
harsh
environ
digest
tract
substanti
amount
ag
administ
inde
extrem
low
ph
stomach
proteolyt
enzym
bile
salt
intestin
presenc
rel
thick
onelay
mucu
overal
low
permeabl
intestin
greatli
affect
integr
deliveri
appli
ag
context
oral
vaccin
like
effici
repeat
dose
given
provid
adjuv
incorpor
avoid
toler
induct
oral
administr
effici
deliveri
rout
achiev
induct
gut
immun
high
import
fight
larg
burden
enteropathogen
infect
worldwid
induct
immun
respons
colon
stomach
mammari
salivari
gland
well
system
also
take
place
limit
robust
sublingu
immun
gener
immun
respons
similar
profil
mucos
tropism
nasal
deliveri
ie
vigor
broadli
dissemin
mucos
system
iga
igg
well
helper
cytotox
cell
respons
without
mani
side
effect
formul
concern
associ
nasal
oral
immun
also
easili
access
selfadministr
shown
induc
immun
respons
administr
solubl
ag
particul
ag
livekil
bacteria
virus
sublingu
deliveri
interest
oral
caviti
milder
environ
may
degrad
vaccin
compon
may
thu
requir
larg
amount
ag
exampl
higher
ab
respons
obtain
mice
sublingu
compar
oral
administr
time
less
ag
appli
one
limit
factor
absenc
agsampl
cell
oral
caviti
line
stratifi
epithelium
rel
low
number
dc
upper
layer
oral
tissu
howev
vaccin
formul
taken
lingual
tonsil
deliveri
region
ln
langerhan
cell
oral
epithelium
shown
act
potent
induc
immun
sever
deliveri
system
microneedl
liposom
inactiv
microorgan
adjuv
tolllik
receptor
tlr
ligand
cholera
toxin
ct
mutant
heat
labil
toxin
lt
ct
evalu
sublingu
vaccin
protect
respons
lung
genit
tract
gut
togeth
siga
saliva
intestin
vagin
wash
obtain
differ
vaccin
formul
vagin
immun
elicit
immun
respons
genit
tissu
secret
effici
induc
system
immun
despit
rel
low
ph
vagina
mild
environ
impair
ag
integr
thu
allow
limit
amount
ag
deliv
howev
presenc
stratifi
epithelium
absenc
induct
site
impli
induct
vaccin
respons
via
vagin
deliveri
requir
specif
adjuv
formul
dc
subset
addit
chang
occur
term
immunolog
function
estrou
cycl
complic
immun
addit
studi
requir
better
understand
mucos
immun
urogenit
tract
defin
specif
requir
vaccin
formul
rectal
immun
abl
induc
potent
immun
respons
small
intestin
colon
effici
system
compart
limit
studi
avail
fulli
appreci
potenti
administr
rout
mucos
vaccin
vaccin
formul
resist
deleteri
environ
mucos
surfac
also
face
addit
hurdl
cross
epithelium
gain
access
underli
apc
context
target
rel
low
number
portal
entri
induc
site
eg
cell
repres
epitheli
cell
enterocyt
within
follicularassoci
epithelium
dc
spread
within
epithelium
asset
effici
vaccin
dc
target
mean
ctype
lectin
receptor
dcsign
mannos
receptor
specif
ab
direct
dc
marker
proven
effici
strategi
improv
potenc
parenter
vaccin
similar
strategi
develop
mucos
vaccin
target
langerin
dc
oral
caviti
esophagu
vagin
mucosa
fcrn
express
airway
gut
epitheli
cell
well
dc
subset
also
demonstr
effici
strategi
deliv
iggbas
complex
across
epithelium
underli
dc
approach
effici
led
induct
cell
effector
respons
galactosyl
ceramid
may
function
target
moieti
intestin
rectum
endocerv
mucosa
gangliosid
molecul
target
specif
peptid
develop
phage
display
far
cell
concern
specif
deliveri
achiev
via
differ
strategi
tight
junction
molecul
bacteri
fimh
receptor
complement
receptor
ligand
mcellspecif
peptid
refer
uniqu
glycosyl
pattern
involv
later
use
ulex
europaeu
specif
monoclon
ab
success
demonstr
howev
human
lack
express
particular
sugar
moieti
cell
togeth
extram
cell
express
preclud
use
strategi
specif
target
purpos
contrast
promis
approach
consist
coupl
vaccin
ag
siga
order
induc
mcellspecif
retrotransport
across
epithelium
dc
target
via
mice
human
ab
molecul
potenti
serv
cargo
control
deliveri
associ
payload
occur
natur
microorgan
sampl
mucos
lumen
addit
advantag
resist
siga
proteas
degrad
abil
anchor
mucu
two
featur
may
improv
stabil
retent
time
associ
ag
size
particul
ag
impact
type
immun
respons
gener
influenc
mechan
uptak
apc
inde
receptormedi
endocytosi
pinocytosi
macropinocytosi
phagocytosi
lead
differ
way
traffick
within
cell
therefor
induc
preferenti
present
via
mhc
mhc
ii
pathway
cell
prime
respect
small
particl
nm
sens
virus
taken
receptormedi
endocytosi
lead
predomin
cell
respons
wherea
larger
particl
nm
taken
via
micropinocytosi
phagocytosi
preferenti
induc
ab
respons
similar
sizedepend
uptak
cell
enterocyt
take
place
lead
differenti
sampl
particul
ag
studi
demonstr
vesicl
smaller
nm
induc
balanc
toward
respons
wherea
opposit
observ
larger
vesicl
moreov
context
mucos
deliveri
size
particl
influenc
tissu
local
diffus
across
mucu
follow
nasal
administr
small
particl
better
transport
across
nasal
mucosa
wherea
larger
one
better
deposit
respiratori
tract
taken
alveolar
macrophag
order
get
access
epithelium
viscos
pore
size
mucu
impact
penetr
vaccin
compon
appar
averag
size
pore
mucu
nm
eg
cervicovagin
small
intestin
mucu
suggest
particl
smaller
cutoff
freeli
diffus
across
mucu
wherea
larger
one
take
time
reach
epithelium
possibl
never
reach
one
major
point
consid
correl
size
immunogen
difficult
strictli
assess
lipidbas
particl
homogen
monodispers
prepar
challeng
obtain
feasibl
prepar
requir
technic
issu
may
dramat
increas
cost
vaccin
formul
diffus
across
mucu
govern
size
particul
ag
mucu
pore
also
chemic
characterist
surfac
charg
particl
hydrophob
electrostat
interact
mediat
particl
aggreg
mucu
microstructur
imped
diffus
vaccin
hydrophil
neutral
vaccin
formul
promot
mucu
penetr
mucoadhes
promot
posit
charg
particl
interact
neg
charg
mucu
exampl
electrostat
interact
cation
lipid
nasal
mucosa
promot
enhanc
contact
time
tissu
higher
local
concentr
thu
improv
penetr
liposom
similarli
cation
particl
better
interact
neg
charg
cell
membran
cell
enterocyt
therefor
limit
vaccin
clearanc
improv
sampl
via
endocytosi
membran
fusion
also
improv
uptak
dc
howev
cation
particl
may
chargedepend
cytotox
target
cell
therefor
densiti
cation
lipid
within
particl
shell
care
defin
tight
balanc
strong
adhes
safeti
achiev
interestingli
seem
presenc
mucu
limit
cytotox
mean
cation
particl
keep
valid
mucos
vaccin
differ
way
associ
ag
lipidbas
deliveri
system
choic
depend
mainli
administr
rout
natur
ag
oral
administr
encapsul
seem
favor
term
ensu
immun
respons
prevent
rapid
degrad
ag
within
gastrointestin
environ
henc
increas
halflif
encapsul
ag
rel
easi
perform
manufactur
process
may
alter
antigen
structur
contrast
mainten
integr
ag
less
affect
nasal
rout
suggest
surfac
associ
via
charg
interact
suffici
approach
technic
demand
owe
opposit
charg
either
particl
ag
favor
altern
coval
bind
surfac
particl
achiev
although
complic
perform
preclud
undesir
releas
payload
may
occur
within
tissu
environ
term
immun
respons
induct
encapsul
within
liposom
preferenti
induc
igg
product
wherea
surfac
display
ag
induc
igm
igg
respons
elev
level
addit
ag
densiti
surfac
particl
well
agtolipid
ratio
document
influenc
elicit
immun
respons
follow
immun
may
suggest
encapsul
surfac
locat
ag
within
formul
would
promot
optim
induct
cell
b
cell
respons
apart
protein
ag
plasmid
dna
code
pathogenderiv
ag
evalu
vaccin
strategi
establish
record
efficaci
preclin
studi
safe
use
human
even
immunocompromis
individu
howev
base
result
obtain
field
veterinari
vaccin
nake
dna
induc
weak
immun
respons
order
improv
immunogen
associ
dna
cation
liposom
lead
increas
uptak
target
cell
deliveri
nucleu
dna
immun
nasal
oral
rout
effect
induc
protect
humor
cellular
immun
relat
mucos
surfac
necessit
associ
cation
deliveri
system
presum
increas
mucu
penetr
reduc
mucociliari
clearanc
improv
permeat
across
epithelium
dna
sequenc
canon
cpg
motif
shown
display
immunostimulatori
properti
similar
way
messeng
rnabas
vaccin
appropriet
protect
ribonucleas
translat
cytoplasm
requir
nuclear
transport
mainli
evalu
cation
lipidbas
vesicl
context
cancer
immunotherapi
effici
nasal
applic
particleassoci
mrna
demonstr
upon
mucos
administr
vaccin
formul
dilut
mucos
fluid
face
bulk
flow
lead
limit
retent
time
suboptim
access
epithelium
sampl
deleteri
effect
compens
incorpor
mucoadhes
mucuspenetr
compon
case
surfac
structur
lipidbas
particl
care
design
obtain
adequ
balanc
strong
adhes
mucu
penetr
possibl
strategi
describ
first
one
consist
incorpor
polyethylen
glycol
peg
surfac
particl
peg
origin
use
system
administr
order
avoid
adsorpt
plasma
protein
format
corona
may
mask
target
ligand
adjuv
ag
surfac
particl
addit
presenc
peg
increas
stabil
upon
administr
similar
stabil
effect
report
case
oral
sublingu
deliveri
liposom
peg
hydrophil
compon
report
help
particl
penetr
nasal
mucosa
prevent
aggreg
thu
facilit
diffus
across
mucos
barrier
moreov
form
hydrogen
bond
mucu
lead
mucoadhes
also
help
diffus
across
mucu
inde
intrigu
bifunction
correl
molecular
weight
peg
high
molecular
weight
polym
preferenti
mucoadhes
wherea
lower
one
better
diffus
within
mucu
addit
nonneglig
advantag
peg
provid
cryopreserv
function
particl
manufactur
second
strategi
associ
micronanoparticl
mucoadhes
compon
chitosan
deacetyl
chitin
algin
polyvinyl
alcohol
hyaluronan
cellulos
deriv
boost
particlebas
vaccin
addit
bioadhes
compon
xanthan
gum
tramella
within
formul
help
increas
viscos
vaccin
thu
retent
time
mucos
surfac
studi
mucoadhes
molecul
chitosan
whose
relev
properti
mucos
vaccin
follow
posit
charg
molecul
interact
neg
charg
mucu
improv
adhes
permeat
enhanc
due
abil
transient
open
epitheli
tight
junction
thu
improv
ag
sampl
adjuv
properti
promot
induct
igg
siga
chitosan
explor
deliveri
via
oral
nasal
pulmonari
rout
associ
liposom
lead
increas
stabil
mucoadhes
absorpt
mucos
surfac
interestingli
demonstr
detriment
effect
toward
mucos
tissu
sever
adjuv
evalu
last
decad
mucos
vaccin
essenti
properti
ideal
adjuv
includ
follow
effect
lowdos
ag
suitabl
mani
differ
ag
effect
enough
reduc
number
vaccin
administr
abl
induc
longterm
immun
respons
display
limit
absent
toxic
innat
immun
trigger
use
adjuv
capac
elicit
proinflammatori
respons
recruit
phagocyt
enhanc
ag
present
apc
activ
apc
order
gener
adequ
environ
effici
prime
adapt
immun
studi
anim
demonstr
import
adjuv
effect
vibrio
cholera
endotoxin
ct
escherichia
coli
lt
ensur
enhanc
ag
permeat
epithelium
enhanc
target
cell
increas
ag
present
dc
improv
activ
dc
direct
effect
b
cell
addit
report
howev
adjuv
inadequ
human
use
toxic
unaccept
side
effect
exampl
induct
deleteri
inflammatori
respons
lead
alter
function
olfactori
nerv
bell
palsi
nasal
administr
diarrhea
symptom
oral
administr
orient
research
toward
gener
less
toxic
deriv
engin
introduct
mutat
subunit
ct
lt
promis
deriv
doubl
mutant
lt
dmlt
demonstr
side
effect
anim
applic
retain
import
adjuv
activ
oral
sublingu
administr
similar
mutat
appli
ct
similarli
reduc
toxic
although
level
still
accept
human
use
introduct
addit
mutat
within
amino
acid
stretch
recent
demonstr
safeti
abil
induc
ab
cell
respons
close
nonmut
ct
follow
nasal
oral
sublingu
vaccin
altern
approach
use
b
subunit
lt
ct
ltb
ctb
effici
via
oral
rout
howev
nasal
administr
demonstr
effici
ag
physic
link
adjuv
result
increas
uptak
across
epithelium
dc
fusion
protein
obtain
associ
subunit
ct
aureu
protein
deriv
prove
effici
boost
b
cell
respons
nasal
administr
anoth
report
edema
toxin
bacillu
anthraci
diphtheria
toxoid
within
lipid
particl
evalu
nasal
administr
show
effici
induct
immun
respons
lead
reduc
bacteri
load
pathogen
challeng
parallel
evalu
immunostimulatori
molecul
activ
parenter
administr
tlr
ligand
perform
cpg
oligodeoxynucleotid
cpg
monophosphoryl
lipid
mpla
flagellin
ligand
respect
administ
oral
intranas
demonstr
immunostimulatori
properti
mucos
immun
respons
includ
induct
siga
pulmonari
deliveri
tuberculosisderiv
ag
togeth
cpg
mpla
promot
gener
product
lung
mpla
potent
induc
product
decreas
bacteri
load
follow
challeng
flagellin
express
differ
pathogen
bacteria
indirectli
stimul
local
dc
follow
nasal
deliveri
induc
mucos
iga
respons
protect
upon
influenza
vaccin
administr
altern
trehalos
dibehen
tdb
synthet
analog
tuberculosi
cord
factor
known
interact
mincl
promot
respons
also
shown
effect
nasal
rout
saponin
also
demonstr
potent
adjuv
effect
nasal
administ
addit
sting
ligand
cdiamp
cdigmp
effici
deliv
via
nasal
sublingu
rout
elicit
respons
highaffin
siga
activ
nkt
cell
administr
also
interest
nasal
oral
sublingu
vaccin
due
abil
enhanc
immunogen
differ
mucos
vaccin
formul
adjuv
incorpor
within
lipidbas
particl
associ
surfac
depend
local
cognat
receptor
target
cell
success
achiev
result
improv
uptak
activ
dc
moreov
cation
lipid
per
se
shown
directli
activ
apc
enorm
potenti
liposom
drug
deliveri
acknowledg
decad
inde
display
featur
includ
control
releas
protect
degrad
improv
pharmacokinet
increas
circul
time
target
specif
tissu
progress
adapt
administr
divers
antigen
entiti
protein
peptid
dna
order
produc
vaccin
formul
fight
sever
viral
bacteri
infect
liposom
spheric
vesicl
consist
unilamellar
multilamellar
shell
phospholipid
bilay
entrap
aqueou
core
rang
size
ten
nanomet
sever
micromet
diamet
amphiphil
natur
phospholipid
mediat
selfassembl
liposom
aqueou
environ
lead
bilay
configur
incorpor
hydrophil
molecul
encapsul
within
aqueou
core
hydrophob
molecul
hook
surfac
insert
within
inner
hydrophob
space
lipid
bilay
biocompat
neutral
anion
phospholipid
phosphatidyl
cholin
eg
distearoylphosphatidylcholin
dspc
cholesterol
commonli
use
constitu
shell
ensur
proper
stabil
structur
improv
immunogen
formul
length
degre
satur
acyl
chain
influenc
permeabl
fluiditi
shell
lead
increas
decreas
stabil
liposom
versatil
deliveri
system
interest
vaccin
formul
physicochem
properti
modul
alter
composit
lipid
among
possibl
modif
ph
titrabl
lipid
induc
control
releas
payload
synthet
cation
lipid
improv
immunogen
gener
addit
function
liposom
specif
target
moieti
emerg
promis
strategi
improv
deliveri
vesicl
bear
dcsignspecif
ligand
lewi
x
glycan
show
increas
dctarget
properti
subsequ
activ
cell
especi
adjuv
iggcoupl
liposom
demonstr
enhanc
transmucos
transport
nasal
tissu
cation
liposom
prepar
dioleoyltrimethylammoniumpropan
dotap
dimethyldioctadecylammonium
bromid
dda
dimethylaminoethanecarbamoyl
dc
cholesterol
success
evalu
nasal
administr
ddabas
liposom
induc
greater
local
vagin
iga
product
compar
vesicl
without
cation
lipid
moreov
incorpor
peg
increas
observ
immun
respons
similarli
deliveri
cation
liposom
compos
dotap
dccholesterol
via
nasal
rout
allow
effici
uptak
dc
nalt
subsequ
induct
specif
iga
cell
nasal
tissu
adjuv
prime
exampl
effici
cation
liposom
use
mucos
vaccin
incorpor
dda
immunostimulatori
molecul
tdb
evalu
sever
anim
model
infect
influenza
chlamydia
tuberculosi
context
presenc
adjuv
substanti
benefici
effect
immunogen
nasal
vaccin
influenza
streptococcu
pyogen
formul
allow
gener
mucos
effector
cell
iga
respons
protect
vaccin
anim
furthermor
prepar
liposom
cation
lipid
ceramid
carbamoylspermin
effici
stimul
system
mucos
immun
follow
intranas
administr
use
cation
prepar
also
interest
approach
altern
form
antigen
entiti
liposom
incorpor
dotap
plasmid
dna
code
mycobacteri
heatshock
protein
given
nasal
induc
local
mucos
immun
respons
abl
reduc
tuberculosi
load
lung
overal
liposomebas
vaccin
via
nasal
rout
lead
induct
robust
immun
respons
whatev
natur
ag
mode
incorpor
thu
finetun
modul
profil
vaccineelicit
respons
appear
depend
composit
formul
includ
type
lipid
andor
presenc
adjuv
interestingli
liposom
prepar
seem
well
toler
induc
limit
inflammatori
respons
irrit
sneez
burn
syndrom
oral
administr
liposom
document
stabil
gastrointestin
tract
remain
main
concern
alreadi
discuss
section
mucoadhes
properti
promis
approach
envisag
improv
stabil
liposom
prepar
incorpor
mannos
chitosan
peg
possibl
scenario
result
reinforc
stabil
better
target
deliveri
across
epithelium
apc
improv
immunogen
stabil
liposom
layerbylay
deposit
polyelectrolyt
also
increas
gener
ab
cell
respons
mucos
tissu
administr
multilamellar
prepar
altern
strategi
final
discuss
section
administr
rout
mucos
vaccin
vaccin
via
sublingu
rout
promis
develop
requir
evalu
liposom
prepar
context
infecti
diseas
exampl
pegmodifi
liposom
incorpor
influenzaderiv
ag
togeth
agonist
adjuv
effect
elicit
elev
level
serum
neutral
ab
mucos
iga
deriv
liposom
explor
circumv
drawback
associ
liposom
improv
effici
exampl
associ
nonion
surfact
cholesterol
deriv
gener
structur
call
niosom
allow
increas
stabil
bilay
vesicl
prevent
oxid
lipid
addit
mannan
surfac
niosom
increas
stabil
vesicl
help
target
specif
receptor
apc
follow
oral
administr
vaccin
niosom
incorpor
plasmid
dna
code
hepat
b
ag
induc
siga
product
salivari
intestin
fluid
togeth
system
cell
respons
moreov
incorpor
bile
salt
within
niosom
structur
bilosom
shown
increas
stabil
vesicl
thu
improv
oral
deliveri
peptid
protein
gut
immun
system
bile
salt
deoxychol
acid
taurochol
acid
amphiphat
molecul
easili
incorpor
within
lipid
bilay
promot
passag
lipophil
compon
across
cell
membran
thu
bilosom
abil
reinforc
biovail
associ
ag
mainli
oral
vaccin
differ
exampl
bilosom
applic
report
associ
hepat
bderiv
ag
tetanu
toxoid
context
induct
siga
mucos
secret
igaposit
plasma
cell
observ
show
elev
respons
compar
parenter
inject
use
niosom
without
bile
salt
altern
approach
inclus
polar
lipid
fulli
satur
isoprenoid
chain
extract
archaea
gener
vesicl
call
archaeosom
archaeal
lipid
mucos
vaccin
adjuv
deliveri
amvad
shown
induc
robust
longlast
protect
ab
cell
respons
includ
cytotox
lymphocyt
respons
system
inject
advantag
structur
mucos
vaccin
compris
increas
phdepend
thermal
stabil
due
prevent
lipid
oxid
resist
phospholipas
bile
salt
context
mice
immun
nasal
rout
demonstr
sustain
robust
local
distant
iga
respons
mucos
fluid
strong
system
igg
respons
cell
respons
addit
nasal
vaccin
archaeosom
cellfre
extract
francisella
tularensi
led
reduc
bacteri
burden
lung
spleen
mous
model
tularemia
oral
immun
archaeosom
possibl
well
although
higher
amount
ag
improv
stabil
retent
time
vesicl
observ
intestin
lead
potent
igg
iga
product
one
nonneglig
drawback
approach
access
achaeal
polar
lipid
purif
archaea
rel
demand
process
nevertheless
product
synthet
polar
lipid
structur
develop
virosom
special
categori
liposom
part
lipid
content
deriv
viral
compon
selfassembl
organ
threedimension
structur
mimic
antigen
structur
origin
viru
interestingli
demonstr
immunogen
without
addit
adjuv
although
addit
immunopotenti
agent
improv
vaccin
effici
origin
call
immunopotenti
reconstitut
influenza
virosom
harbor
hemagglutinin
neuraminidas
protein
influenza
viru
protein
target
sialic
acid
cell
membran
lead
fusion
target
cell
virosom
follow
intracellular
deliveri
payload
exhibit
similar
flexibl
advantag
standard
liposom
howev
process
extract
necessari
compon
influenza
viru
rel
complex
virosom
mainli
investig
parenter
vaccin
report
use
mucos
administr
exist
use
primeboost
vaccin
strategi
simian
model
hiv
infect
intramuscular
inject
follow
nasal
administr
induc
full
protect
vagin
simianhiv
challeng
correl
presenc
mucos
iga
igg
block
activ
viru
transcytosi
neutralizingabdepend
cellular
cytotox
properti
respect
mice
nasal
sublingu
administr
adjuv
virosom
abl
protect
influenza
respiratori
syncyti
viru
infect
promot
mucos
system
ab
respons
togeth
cellular
respons
gasfil
microbubbl
micros
spheric
structur
compos
lipid
denatur
proteinbas
crosslink
polym
shell
gener
entrap
inert
high
molecular
weight
gase
ensur
resist
pressur
administ
due
strong
echogen
presenc
low
ultrasound
intens
current
use
human
applic
intraven
deliv
echocontrast
agent
precis
visual
exampl
angiogenesi
malign
tumor
left
ventricular
opacif
myocardi
perfus
addit
cavit
induc
higher
ultrasound
applic
lead
transient
nonleth
permeabl
surround
tissu
eg
vascular
barrier
cell
membran
allow
enhanc
local
ondemand
extravas
bioavailabilti
microbubbleassoci
payload
last
decad
process
known
sonopor
receiv
import
attent
order
improv
deliveri
wide
rang
therapeut
molecul
includ
chemotherapeut
agent
sirna
mirna
oligonucleotid
plasmid
dna
tumor
immun
cell
typic
sonopor
use
improv
deliveri
ag
dc
aim
boost
immun
respons
interestingli
lipidbas
microbubbl
taken
apc
deliv
intracellularli
antigen
payload
without
ultrasound
applic
lead
process
present
ag
respons
cell
furthermor
microbubbleassoci
ag
inject
parenter
vaccin
formul
elicit
potent
longlast
immun
respons
system
bacteri
infect
lipidbas
microbubbl
usual
compos
phospholipid
eg
dspc
palmit
acid
tailor
formul
prepar
incorpor
cation
lipid
shell
order
better
associ
dna
addit
improv
specif
imag
drug
deliveri
microbubbl
target
particular
tissu
link
cellspecif
ligand
ab
develop
surfac
aspect
interest
mucos
vaccin
use
target
strategi
discuss
section
target
deliveri
vaccin
ag
moreov
adjuv
associ
microbubbl
result
enhanc
immunogen
vaccin
prepar
exampl
nasal
deliveri
microbubbl
display
salmonelladeriv
sseb
ag
surfac
abl
induc
potent
iga
igm
igg
humor
respons
gut
associ
cellular
respons
result
signific
decreas
local
system
bacteri
load
follow
oral
infect
salmonella
enterica
typhimurium
prophylact
vaccin
mice
effect
potent
parenter
inject
microbubbl
formul
despit
far
limit
induct
local
immun
respons
oral
administr
improv
microbubbl
formul
may
lead
enhanc
immunogen
moreov
sublingu
administr
remain
test
owe
valuabl
advantag
context
mucos
vaccin
recent
year
nanos
bubbl
develop
show
increas
stabil
extravas
follow
system
administr
suggest
deriv
might
even
suitabl
vaccin
purpos
immun
stimul
complex
iscom
neg
charg
selfassembl
pentagon
dodecahedron
cagelik
rigid
structur
size
nm
form
spontan
mix
ag
cholesterol
phospholipid
usual
phosphatidylethanolamin
phosphatidylcholin
saponin
quil
extract
bark
quillaja
saponaria
molina
tree
interestingli
formul
allow
reduc
toxic
associ
saponin
administr
retain
adjuv
activ
protein
glycoprotein
normal
anchor
hydrophob
transmembran
sequenc
cell
membran
incorpor
nonamphipat
protein
peptid
modifi
attach
lipid
tail
eg
palmit
acid
immun
iscom
induc
humor
cellular
respons
includ
cytotox
lymphocyt
import
fight
intracellular
pathogen
sever
studi
report
potent
induct
mucos
immun
respons
includ
robust
iga
product
nasal
wash
lung
nasalpulmonari
vaccin
iscom
harbor
antigen
entiti
influenza
viru
respiratori
synciti
viru
hepat
b
viru
measl
protect
efficaci
observ
well
vaccin
influenza
subunit
vaccin
compos
iscom
adjuv
iscombas
antim
tuberculosi
antiinfluenza
vaccin
helicobact
pyloriag
deliv
via
iscom
case
immun
prove
effici
parenter
inject
product
iscom
altern
saponin
deriv
quilaja
brasiliensi
also
allow
induc
mucos
local
distant
iga
product
nasal
deliveri
ovabas
vaccin
addit
incorpor
dna
plasmid
within
iscom
matrix
elicit
potent
antihaemophilu
influenza
cellular
ab
respons
nasopharynx
nasal
immun
anim
oral
administr
iscombas
vaccin
evalu
howev
seem
gener
intestin
iga
respons
limit
although
iscom
selfadjuv
deliveri
system
incorpor
adjuv
within
structur
allow
induc
robust
mucos
iga
product
cell
prolifer
togeth
system
respons
nasal
administr
approach
also
evalu
via
oral
deliveri
potent
system
immun
respons
induc
unfortun
mucos
compart
analyz
incorpor
major
outer
membran
protein
chlamydia
muridarum
also
administ
via
vagin
rout
vaccin
induc
limit
ab
respons
clearli
detect
cell
respons
vagin
tissu
led
protect
bacteri
challeng
demonstr
reduct
bacteri
shed
genit
tract
overal
use
iscom
deliveri
vehicl
mucos
vaccin
find
best
applic
nasal
administr
even
though
sublingu
rout
remain
explor
nevertheless
difficulti
relat
use
hydrophil
ag
modifi
incorpor
within
iscom
togeth
report
toxic
saponin
somehow
limit
wide
use
vaccin
approach
oilinwat
nanoemuls
dispers
nanos
droplet
exhibit
longterm
colloid
stabil
encapsul
hydrophil
hydrophob
payload
respect
test
nasal
vaccin
nanoemuls
base
soybean
oil
cetylpiridinium
chlorid
shown
deliv
antigen
payload
across
ciliat
nasal
epitheli
cell
region
ln
nalt
migrat
activ
dc
via
vaccin
formul
promot
induct
robust
ab
cellular
respons
associ
inactiv
influenza
vaccin
gener
protect
immun
influenza
challeng
approach
similarli
prove
effici
anim
model
fight
tuberculosi
hepat
b
bacillu
anthraci
infect
gener
mucos
immun
respons
improv
stabil
nanoemuls
mucos
deliveri
achiev
doubl
emuls
waterinoilinwat
technolog
appli
nasal
oral
result
robust
product
system
igg
mucos
iga
altern
coupl
lipopeptid
polylysin
core
induc
format
nm
particl
promot
gener
system
mucos
iggiga
cell
respons
nasal
administr
condit
protect
respons
obtain
pyogen
infect
current
approv
mucos
vaccin
compos
liveattenu
kill
wholepathogen
cell
offer
rel
good
efficaci
administ
young
infant
immunocompromis
peopl
elderli
due
potenti
safeti
issu
major
mucos
administ
vaccin
human
deliv
via
oral
rout
direct
enter
infect
polio
cholera
typhoid
fever
rotaviru
infect
oral
polio
vaccin
use
year
great
success
prototyp
vaccin
polio
erad
mani
countri
interestingli
demonstr
improv
efficaci
compar
inactiv
pathogen
vaccin
inject
parenter
well
liveattenu
wholekil
vaccin
salmonellainduc
typhoid
fever
vibrio
cholera
infect
respect
expect
base
preclin
studi
anim
model
protect
efficaci
correl
effector
immun
respons
present
mucos
surfac
case
detect
siga
mucos
fluid
induct
plasma
cell
express
guthom
molecul
specif
small
intestin
colon
addit
similar
observ
anim
model
choic
administr
rout
impact
tropism
induc
mucos
immun
respons
liveattenu
influenza
viru
vaccin
licens
nasal
administr
demonstr
high
level
protect
match
mismatch
viral
strain
children
adult
prove
effici
parenter
vaccin
virusspecif
mucos
iga
system
igg
respons
possibl
role
cellmedi
immun
document
vaccin
individu
far
adjuv
use
vaccin
applic
mucosa
b
subunit
ct
includ
improv
immunogen
kill
wholepathogen
vibrio
cholera
vaccin
despit
mani
encourag
result
obtain
proofofconcept
preclin
anim
model
limit
number
subunit
vaccin
base
lipid
deliveri
system
evalu
andor
approv
human
use
especi
mucos
administr
tabl
interestingli
context
mucos
vaccin
least
three
formul
evalu
earli
phase
clinic
trial
nasal
administr
oilinwat
nanoemuls
combin
approv
inactiv
system
influenza
vaccin
demonstr
induct
iga
respons
nasal
wash
clinic
evalu
addit
virosomebas
iscombas
influenza
vaccin
current
develop
administr
via
nasal
rout
system
inject
virosom
licens
human
vaccin
hepat
influenza
inflex
addit
vaccin
base
technolog
test
phase
clinic
trial
malaria
influenza
via
system
rout
advantag
approach
virosom
selfadjuv
case
lipidbas
deliveri
system
two
influenza
vaccin
formul
compos
squalenebas
nanoemuls
also
approv
intramuscular
inject
human
particular
focu
use
young
children
elderli
least
three
addit
strategi
evalu
human
promis
one
use
adjuv
compos
liposom
made
highli
unsatur
neutral
phospholipid
includ
mpla
saponin
success
phase
iii
vaccin
trial
deliveri
system
perform
rt
vaccin
formul
malaria
herpeszoost
vaccin
hzsu
altern
formul
current
test
parenter
vaccin
tuberculosi
liposom
bilay
prepar
contain
cation
lipid
dda
glycolipid
tdb
immunostimul
iscom
incorpor
ag
test
women
cervic
intraepitheli
neoplasia
hivposit
individu
oncogen
hpv
infect
demonstr
safeti
profil
induc
specif
humor
effector
cell
respons
similar
result
obtain
follow
vaccin
hcvderiv
antigen
entiti
addit
vaccin
prepar
base
lipid
construct
current
evalu
fight
pathogen
infect
malaria
dengu
fever
hiv
influenza
nevertheless
abovement
studi
mainli
perform
system
inject
formul
rare
mucos
applic
assess
use
mucos
rout
administr
requir
anatom
function
immunolog
characterist
taken
consider
differ
human
anim
may
result
poor
interspeci
translat
promis
result
organ
nalt
similar
present
mice
found
human
contrast
altern
induct
site
form
immun
nodul
present
human
upper
nasal
caviti
concha
waldey
ring
adenoid
tonsil
pulmonari
deliveri
vaccin
seem
optim
well
balt
report
fetus
young
children
healthi
adult
addit
local
phenotyp
dc
nasal
caviti
lung
differ
mice
human
take
account
consider
sublingu
administr
sound
like
promis
strategi
inde
immunolog
physiolog
organ
oral
caviti
similar
mice
human
document
presenc
dc
subset
langerhan
cell
capabl
elicit
immunogen
tolerogen
respons
depend
appli
formul
vaccin
via
sublingu
rout
mostli
evalu
human
allergen
immunotherapi
shown
induc
system
igg
focu
allergi
therefor
evalu
mucos
vaccin
approach
protect
infecti
diseas
highli
relev
need
evalu
addit
although
gut
immun
system
rel
similar
speci
oral
administr
subunit
vaccin
complic
due
constraint
relat
stabil
formul
aggress
environ
digest
tract
top
anatom
consider
agerel
declin
immun
function
possibl
relat
document
decreas
cell
differenti
age
repres
drawback
immun
elderi
peopl
although
vaccin
led
control
sever
diseas
demonstr
substanti
technolog
progress
human
still
suffer
infect
lead
death
increas
health
cost
mani
infecti
diseas
develop
effect
vaccin
urgent
need
includ
transmit
variou
mucos
rout
affect
gastrointestin
tract
e
coli
salmonella
shigella
vibrio
cholera
h
pylori
respiratori
tract
influenza
tuberculosi
respiratori
synciti
viru
sexual
transmit
hiv
chlamydia
date
parenter
vaccin
repres
import
part
administ
vaccin
despit
fact
poorli
induc
mucos
immun
respons
furthermor
requir
steril
needl
subsequ
elimin
associ
cost
cold
chain
requir
mani
instanc
prompt
shift
toward
reduc
frequenc
intramuscular
vaccin
addit
current
licens
vaccin
administ
year
age
safeti
reason
similar
consider
appli
immunodefici
individu
elderli
therefor
mucos
applic
subunit
vaccin
repres
sound
altern
broaden
target
popul
could
benefit
vaccin
cue
direct
includ
recent
advanc
understand
mucos
immun
well
assess
correl
protect
may
help
develop
promis
mucos
vaccin
respect
design
novel
effect
deliveri
strategi
permit
achiev
mucos
vaccin
induc
protect
neutral
siga
togeth
ctl
effector
cell
mainli
secret
moreov
consid
safe
subunit
vaccin
certainli
administ
neonat
young
infant
alreadi
possess
function
mucos
immun
system
lipidbas
particl
fulfil
requir
better
effici
safeti
lowdos
ag
eas
handl
logist
deliv
wide
rang
antigen
entiti
upon
mucos
deliveri
tailor
obtain
vaccin
formul
appropri
properti
address
question
relat
mechan
invlolv
control
pathogen
rout
administr
robust
sustain
induct
immun
respons
compris
product
siga
mucos
surfac
togeth
helper
cytotox
cell
often
correl
protect
defin
anim
model
studi
undoubtli
help
drive
vaccin
develop
toward
right
direct
remain
strict
compar
analysi
formul
administr
rout
use
particular
infecti
diseas
rare
perform
within
studi
contribut
identif
miss
piec
complex
puzzl
would
asset
order
optim
mucos
vaccin
lack
inform
must
fill
one
deal
definit
optim
dose
schedul
administr
ensur
effici
prime
boost
immun
respons
aim
reach
optim
magnitud
mainten
lipidbas
prepar
advantag
lyophil
thu
allow
simplifi
logist
usual
necessari
cold
chain
inde
formul
store
room
temperatur
sever
month
administ
form
via
nasal
oral
sublingu
rout
dri
powder
nasal
vaccin
alreadi
test
oral
deliveri
capsul
problem
mani
allergyrel
immunotherapi
tablet
consid
sublingu
administr
moreov
lipidbas
prepar
aerosol
might
repres
altern
procedur
keep
stabl
vaccin
prepar
overal
great
expect
come
lipidbas
vaccin
formul
current
evalu
clinic
trial
human
togeth
differ
mechan
mucos
immun
recent
unravel
may
like
favor
develop
futur
mucos
vaccin
suitabl
major
individu
thank
combinatori
flexibl
offer
natur
constitu
avail
bc
gb
plan
manuscript
wrote
section
manuscript
author
read
approv
submit
version
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
